Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eberhard L Renner

Showing results (11-20 of 65) with videos related to

Pageof 7
Sort By:
Canadian Journal of Gastroenterology & Hepatology|November 12, 2013
One year of hepatitis B immunoglobulin plus tenofovir therapy is safe and effective in preventing recurrent hepatitis B post-liver transplantationTomohiro Tanaka, Eberhard L Renner, Nazia Selzner, et al.
Transplant International : Official Journal of the European Society for Organ Transplantation|November 10, 2012
Virological response for recurrent hepatitis C improves long-term survival in liver transplant recipientsTomohiro Tanaka, Nazia Selzner, George Therapondos, et al.
Canadian Journal of Gastroenterology = Journal Canadien De Gastroenterologie|March 22, 2013
Serum aspartate aminotransferase levels and previous histopathological findings enable reduction of protocol liver biopsies after liver transplantation for hepatitis CTomohiro Tanaka, George Therapondos, Nazia Selzner, et al.
Liver Transplantation : Official Publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society|November 26, 2014
Outcomes of patients with cirrhosis and hepatorenal syndrome type 1 treated with liver transplantationFlorence Wong, Wesley Leung, Mohammed Al Beshir, et al.
Swiss Medical Weekly|August 21, 2007
Interferon and ribavirin with or without amantadine for interferon non-responders with chronic hepatitis C. A randomized, controlled pilot studyChrista Wenger, Thomas Bischof, Jean-Jacques Gonvers, et al.
Transplant Infectious Disease : an Official Journal of the Transplantation Society|June 15, 2017
The effect of different immunoprophylaxis regimens on post-transplant cytomegalovirus (CMV) infection in CMV-seropositive liver transplant recipientsChian Yong Low, Seyed Mohammadmehdi Hosseini-Moghaddam, Coleman Rotstein, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|April 18, 2003
Successful use of the Molecular Adsorbent Recirculating System (MARS) in a patient with primary biliary cirrhosis (PBC) and treatment refractory pruritusBeat Mullhaupt, Gerd A. Kullak-Ublick, Patrice M. Ambühl, et al.
Transplantation|September 28, 2002
Living donor liver transplantation in patients with portal vein thrombosis: a survey and review of technical issuesZakiyah Kadry, Nazia Selzner, Alexander Handschin, et al.
Canadian Journal of Gastroenterology & Hepatology|June 16, 2015
Post-transplant lymphoproliferative disorder in liver recipients: Characteristics, management, and outcome from a single-centre experience with >1000 liver transplantationsKhalid Mumtaz, Nabiha Faisal, Max Marquez, et al.
Clinical Transplantation|October 16, 2012
The long-term efficacy of nucleos(t)ide analog plus a year of low-dose HBIG to prevent HBV recurrence post-liver transplantationTomohiro Tanaka, Ali Benmousa, Max Marquez, et al.
Pageof 7

Showing results (11-20 of 65) with videos related to

Sort By:
Pageof 7
Canadian Journal of Gastroenterology & Hepatology|November 12, 2013
One year of hepatitis B immunoglobulin plus tenofovir therapy is safe and effective in preventing recurrent hepatitis B post-liver transplantationTomohiro Tanaka, Eberhard L Renner, Nazia Selzner, et al.
Transplant International : Official Journal of the European Society for Organ Transplantation|November 10, 2012
Virological response for recurrent hepatitis C improves long-term survival in liver transplant recipientsTomohiro Tanaka, Nazia Selzner, George Therapondos, et al.
Canadian Journal of Gastroenterology = Journal Canadien De Gastroenterologie|March 22, 2013
Serum aspartate aminotransferase levels and previous histopathological findings enable reduction of protocol liver biopsies after liver transplantation for hepatitis CTomohiro Tanaka, George Therapondos, Nazia Selzner, et al.
Liver Transplantation : Official Publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society|November 26, 2014
Outcomes of patients with cirrhosis and hepatorenal syndrome type 1 treated with liver transplantationFlorence Wong, Wesley Leung, Mohammed Al Beshir, et al.
Swiss Medical Weekly|August 21, 2007
Interferon and ribavirin with or without amantadine for interferon non-responders with chronic hepatitis C. A randomized, controlled pilot studyChrista Wenger, Thomas Bischof, Jean-Jacques Gonvers, et al.
Transplant Infectious Disease : an Official Journal of the Transplantation Society|June 15, 2017
The effect of different immunoprophylaxis regimens on post-transplant cytomegalovirus (CMV) infection in CMV-seropositive liver transplant recipientsChian Yong Low, Seyed Mohammadmehdi Hosseini-Moghaddam, Coleman Rotstein, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|April 18, 2003
Successful use of the Molecular Adsorbent Recirculating System (MARS) in a patient with primary biliary cirrhosis (PBC) and treatment refractory pruritusBeat Mullhaupt, Gerd A. Kullak-Ublick, Patrice M. Ambühl, et al.
Transplantation|September 28, 2002
Living donor liver transplantation in patients with portal vein thrombosis: a survey and review of technical issuesZakiyah Kadry, Nazia Selzner, Alexander Handschin, et al.
Canadian Journal of Gastroenterology & Hepatology|June 16, 2015
Post-transplant lymphoproliferative disorder in liver recipients: Characteristics, management, and outcome from a single-centre experience with >1000 liver transplantationsKhalid Mumtaz, Nabiha Faisal, Max Marquez, et al.
Clinical Transplantation|October 16, 2012
The long-term efficacy of nucleos(t)ide analog plus a year of low-dose HBIG to prevent HBV recurrence post-liver transplantationTomohiro Tanaka, Ali Benmousa, Max Marquez, et al.
Pageof 7